LEXEO Therapeutics
19 articles about LEXEO Therapeutics
-
LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/2/2023
LEXEO Therapeutics announced today that new data supporting its cardiac and neurological gene therapy programs will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 16-20, 2023.
-
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
1/5/2023
LEXEO Therapeutics, Inc. today announced the expansion of its leadership team, with the appointment of Micah Zajic as Chief Financial Officer and Paula H.J. Cholmondeley to its Board of Directors as Audit Committee Chair.
-
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
LEXEO Therapeutics, Inc. today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 10:30 AM PT.
-
Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
11/7/2022
Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
-
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
11/2/2022
LEXEO Therapeutics, Inc. today announced a new executive appointment, as well as the development of a Scientific Advisory Board.
-
LEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences
10/27/2022
LEXEO Therapeutics (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for cardiovascular and central nervous system (CNS) diseases, today announced it will be presenting clinical and preclinical data at three upcoming scientific meetings.
-
LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
10/18/2022
LEXEO Therapeutics today announced that the European Commission has granted Orphan Drug Designation to LX1004 for the treatment of CLN2 Batten disease.
-
LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
10/5/2022
LEXEO Therapeutics, Inc. announced new clinical data from its ongoing study of LX1001 for APOE4-associated Alzheimer’s disease will be presented at the 29th European Society of Gene and Cell Therapy Annual Meeting, which is being held live in Edinburgh, Scotland and virtually from October 11-14, 2022.
-
LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/3/2022
LEXEO Therapeutics today announced that new preclinical data supporting its plakophilin-2 (PKP2) will be presented at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which is being held live in Washington, D.C. and virtually from May 16-19, 2022.
-
LEXEO Therapeutics to Participate in Upcoming Investor Conferences
3/21/2022
LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a deep and diverse pipeline of adeno-associated virus (AAV)-based gene therapy candidates for genetically defined cardiovascular and central nervous system (CNS) diseases, announced today that R. Nolan Townsend, Chief Executive Officer of LEXEO, will participate in the following upcoming investor conferences.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
LEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease
3/2/2022
LEXEO Therapeutics announced today positive initial expression and biomarker data from the low-dose cohort (cohort 1) of its ongoing Phase 1/2 clinical trial of LX1001.
-
LEXEO Therapeutics has announced positive initial data from its Phase I/II trial of LX1001, a gene therapy intended for the treatment of APOE4 homozygous Alzheimer’s disease (AD).
-
LEXEO Therapeutics Announces FDA Clearance of Investigational New Drug Application for LX2006, an AAV-based Gene Therapy Candidate for Friedreich’s Ataxia Cardiomyopathy
2/16/2022
LEXEO Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LX2006.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
LEXEO Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference.
-
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases
10/13/2021
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies today announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies.
-
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
-
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
1/7/2021
LEXEO Therapeutics, a clinical-stage gene therapy company, debuted today with an oversubscribed $85 million Series A financing, led by Longitude Capital and Omega Funds, and joined by Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Invus, Woodline Partners LP, the Alzheimer’s Drug Discovery Foundationi and Alexandria Venture Investments